| Identification | Back Directory | [Name]
1,2,4-Triazolo[4,3-a]pyridine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- | [CAS]
2392951-18-5 | [Synonyms]
Vormatrigine
1,2,4-Triazolo[4,3-a]pyridine, 3-(ethoxydifluoromethyl)-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- | [Molecular Formula]
C16H12F6N4O2 | [MOL File]
2392951-18-5.mol | [Molecular Weight]
406.28 |
| Hazard Information | Back Directory | [Uses]
Vormatrigine is an orally active sodium channel inhibitor with anti-epileptic activity. Vormatrigine has a specific inhibitory effect on overactive NaV channels in vitro and has a good inhibitory effect in the maximal electroconvulsive seizure (MES) model. Vormatrigine can be used to study human focal and generalized epilepsy[1][2]. | [References]
[1] Praxis Precision Medicines, Inc. Preparation of pyridin-3-yl substituted triazolopyrazines, triazolopyridazines, and triazolopyridines as ion channel modulators. World Intellectual Property Organization, WO2019232209 A1 2019-12-05
[2] Praxis Presentation of Epilepsy Program Advances Set for 2024 American Epilepsy Society Annual Meeting |
|
|